[{"id":"a144cd9e-434c-4be9-b736-f65a44ecb8d2","acronym":"","url":"https://clinicaltrials.gov/study/NCT03709446","created_at":"2021-11-12T16:53:39.675Z","updated_at":"2024-07-02T16:35:00.075Z","phase":"Phase 1/2","brief_title":"Leflunomide in Previously Treated Metastatic Triple Negative Cancers","source_id_and_acronym":"NCT03709446","lead_sponsor":"Joseph Sparano","biomarkers":" HER-2 • ER • PIK3CA","pipe":" | ","alterations":" ER positive • HER-2 negative • PIK3CA mutation","tags":["HER-2 • ER • PIK3CA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • PIK3CA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e leflunomide"],"overall_status":"Recruiting","enrollment":" Enrollment 54","initiation":"Initiation: 04/16/2019","start_date":" 04/16/2019","primary_txt":" Primary completion: 10/01/2025","primary_completion_date":" 10/01/2025","study_txt":" Completion: 10/01/2026","study_completion_date":" 10/01/2026","last_update_posted":"2024-05-30"},{"id":"b9206b8e-f067-4cfc-b28d-58df478d8a27","acronym":"","url":"https://clinicaltrials.gov/study/NCT04609826","created_at":"2021-09-24T16:53:15.037Z","updated_at":"2024-07-02T16:35:01.156Z","phase":"Phase 1","brief_title":"A Study of JNJ-74856665 in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)","source_id_and_acronym":"NCT04609826","lead_sponsor":"Janssen Research \u0026 Development, LLC","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e JNJ-6665"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 153","initiation":"Initiation: 11/26/2020","start_date":" 11/26/2020","primary_txt":" Primary completion: 07/31/2024","primary_completion_date":" 07/31/2024","study_txt":" Completion: 07/31/2024","study_completion_date":" 07/31/2024","last_update_posted":"2024-05-24"},{"id":"5e59385c-b0a6-4594-9da3-ea1896923dc1","acronym":"NТО-RAS","url":"https://clinicaltrials.gov/study/NCT06229340","created_at":"2024-01-29T17:21:16.419Z","updated_at":"2024-07-02T16:35:21.987Z","phase":"Phase 2","brief_title":"Leflunomide or Combination of MEK Inhibitor and Hydroxychloroquine for Refractory Patients With RAS Mutations","source_id_and_acronym":"NCT06229340 - NТО-RAS","lead_sponsor":"N.N. Petrov National Medical Research Center of Oncology","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • hydroxychloroquine • leflunomide"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 10/03/2023","start_date":" 10/03/2023","primary_txt":" Primary completion: 10/01/2026","primary_completion_date":" 10/01/2026","study_txt":" Completion: 10/01/2026","study_completion_date":" 10/01/2026","last_update_posted":"2024-01-29"},{"id":"6428c24f-062b-49d2-a05b-9215f1b97e26","acronym":"","url":"https://clinicaltrials.gov/study/NCT04997993","created_at":"2021-08-10T14:52:49.902Z","updated_at":"2024-07-02T16:35:24.882Z","phase":"Phase 1","brief_title":"Leflunomide in Patients With PTEN-[] Advanced Solid Malignancies","source_id_and_acronym":"NCT04997993","lead_sponsor":"Deborah Doroshow","biomarkers":" PTEN","pipe":" | ","alterations":" PTEN expression","tags":["PTEN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTEN expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e leflunomide"],"overall_status":"Recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 12/13/2023","start_date":" 12/13/2023","primary_txt":" Primary completion: 09/01/2026","primary_completion_date":" 09/01/2026","study_txt":" Completion: 09/01/2026","study_completion_date":" 09/01/2026","last_update_posted":"2023-12-29"},{"id":"ddddb0c6-f7f5-4ac6-a188-f261d868f474","acronym":"","url":"https://clinicaltrials.gov/study/NCT05061251","created_at":"2021-09-29T11:53:53.576Z","updated_at":"2025-02-25T17:25:16.827Z","phase":"Phase 1","brief_title":"Surgical Window of Opportunity Study of Orally Administered BAY 2402234 in Recurrent Glioma","source_id_and_acronym":"NCT05061251","lead_sponsor":"University of Texas Southwestern Medical Center","biomarkers":" IDH1 • IDH2","pipe":" | ","alterations":" IDH2 mutation","tags":["IDH1 • IDH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e orludodstat (BAY2402234)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 12/01/2021","start_date":" 12/01/2021","primary_txt":" Primary completion: 12/01/2022","primary_completion_date":" 12/01/2022","study_txt":" Completion: 12/01/2023","study_completion_date":" 12/01/2023","last_update_posted":"2022-01-11"}]